Danske Bank A S Acquires Shares of 583,026 Elanco Animal Health Incorporated $ELAN

Danske Bank A S acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 583,026 shares of the company’s stock, valued at approximately $14,348,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. NewEdge Advisors LLC boosted its stake in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health during the 2nd quarter worth approximately $38,000. Root Financial Partners LLC raised its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $41,000. Finally, Torren Management LLC bought a new position in shares of Elanco Animal Health in the fourth quarter valued at approximately $46,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 4.2%

Elanco Animal Health stock opened at $23.47 on Friday. The firm has a 50 day moving average price of $24.56 and a 200-day moving average price of $24.01. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a twelve month low of $17.11 and a twelve month high of $27.98. The company has a market capitalization of $11.73 billion, a P/E ratio of -57.24, a P/E/G ratio of 1.47 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the firm posted $0.26 EPS. Elanco Animal Health’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on ELAN. Citigroup lifted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. TD Cowen increased their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. UBS Group lifted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Insider Transactions at Elanco Animal Health

In other news, Director Paul Herendeen purchased 10,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the purchase, the director owned 111,687 shares of the company’s stock, valued at $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael J. Harrington acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average cost of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director owned 131,451 shares in the company, valued at $2,868,260.82. The trade was a 3.95% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 23,198 shares of company stock valued at $537,109. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.